Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Taurine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Acamprosate in Fragile x Syndrome

NCT01911455
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
acamprosate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 23 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Phase 2 Interventional

Acamprosate Treatment: Mechanisms of Action

NCT00004552
View directory record Official record
Conditions
Alcoholism
Interventions
acamprosate (Campral)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Study of Acamprosate in Autism

NCT01813318
View directory record Official record
Conditions
Autistic Disorder
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 14, 2026, 8:03 AM EDT
Terminated Phase 4 Interventional Results available

Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees

NCT00249379
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Acamprosate
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Acamprosate to Reduce Symptoms of Alcohol Withdrawal

NCT00106106
View directory record Official record
Conditions
Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Healthy Volunteer
Interventions
NMR-spectroscopy, Oral acamprosate
Procedure · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
21 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Sep 14, 2026, 8:03 AM EDT
Recruiting Phase 4 Interventional

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

NCT06269627
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Acamprosate calcium, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 14, 2026, 8:03 AM EDT
Withdrawn Phase 4 Interventional

Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)

NCT00655967
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Acamprosate (Campral), Acamprosate
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 14, 2026, 8:03 AM EDT
Terminated Not applicable Interventional

Effects of TUDCA on Endothelial Function in Type 2 DM

NCT03462940
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Response, Endothelial Dysfunction
Interventions
Tauroursodeoxycholic acid
Dietary Supplement
Lead sponsor
Boston University
Other
Eligibility
21 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants

NCT00591565
View directory record Official record
Conditions
Anxiety
Interventions
Acamprosate
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 64 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 14, 2026, 8:03 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Acamprosate and Methazolamide for Essential Tremor

NCT06312800
View directory record Official record
Conditions
Essential Tremor
Interventions
Acamprosate, Placebo, Methazolamide
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism

NCT00463346
View directory record Official record
Conditions
Alcohol Dependence, Schizophrenia
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Results available

Biomarker Study of Acamprosate in Schizophrenia

NCT00688324
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Acamprosate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigation of Dietary Supplement Liquid Shot Products on Mental Energy, Cognition (Acuity),and Mood

NCT06384586
View directory record Official record
Conditions
Cognition, Mental Fatigue, Mood
Interventions
Placebo shot, Functional energy shot
Dietary Supplement
Lead sponsor
The Water Street Collective
Industry
Eligibility
18 Years to 30 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Iselin, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 14, 2026, 8:03 AM EDT
Recruiting Not applicable Interventional

Daily Amino Acid Supplementation for People With Parkinson's Disease

NCT07115563
View directory record Official record
Conditions
Parkinson Disease (PD)
Interventions
Targeted Amino Acid Supplement, Control (placebo)
Dietary Supplement
Lead sponsor
Cristina Colon-Semenza
Other
Eligibility
50 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Farmington, Connecticut • Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diet Modulation of Bacterial Sulfur and Bile Acid Metabolism and Colon Cancer Risk

NCT03550885
View directory record Official record
Conditions
Colorectal Cancer
Interventions
High taurine and saturated fat diet, Low in taurine and saturated fat diet
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
45 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Phase 2 Interventional

Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study

NCT00217165
View directory record Official record
Conditions
Bipolar Disorder, Mania, Bipolar Depression
Interventions
taurine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 68 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

NCT00605904
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Yohimbine, mCPP, Saline
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Medication Development in Alcoholism: Acamprosate Versus Naltrexone

NCT00656630
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Naltrexone, Placebo
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Assess the Effects of a Vitamin Shot on Energy Levels

NCT06019858
View directory record Official record
Conditions
Energy, Fatigue, Mood, Weight Loss, Cognition
Interventions
Vitamin Energy Shot
Other
Lead sponsor
Vitamin Energy®
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Phase 3 Interventional

COMBINE (Acamprosate/Naltrexone)

NCT00006206
View directory record Official record
Conditions
Alcoholism
Interventions
naltrexone (Revia), acamprosate (Campral)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
1,375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
12
States / cities
New Haven, Connecticut • Miami, Florida • Belmont, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2010 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Assess Colonic Microbiota Changes in Response to Energy Drink Consumption

NCT06137248
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Energy drink
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence

NCT00385268
View directory record Official record
Conditions
Cocaine Dependence
Interventions
acamprosate, placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

NCT01381354
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet, Omega 3 fatty acids, Full Spectrum vitamin, Essential - hydroxytyrosol, Maltodextrin fiber supplement, Mineral boost (magnesium), Niacinamide, Methyl B12, Taurine, creatine, thiamine, riboflavin, N acetylcysteine, alpha lipoic acid, L acetyl carnitine, methyl folate, coenzyme Q, meditation, self massage, learning, Coconut oil
Other · Device · Dietary Supplement + 1 more
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 14, 2026, 8:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction

NCT00571922
View directory record Official record
Conditions
Methamphetamine Dependence, Treatment Seeking
Interventions
Acamprosate, placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 14, 2026, 8:03 AM EDT